Document:

EX-10.8

 Exhibit 10.8 

Execution Version 
 PATENT
ASSIGNMENT 
 between 

CARDIFF PROTIDES LIMITED 

and 
 NUCANA BIOMED
LIMITED 
 Dated: 15th March 2012 

Ref: [***] 

  
 Portions of this
Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

 INDEX 
  

							
	CLAUSE	 	 	  	PAGE	 
	 1.
	 	Definitions and Interpretation	  	 	1	 
	 2.
	 	Assignment	  	 	2	 
	 3.
	 	Warranties and Liabilities	  	 	3	 
	 4.
	 	Entire Agreement	  	 	3	 
	 5.
	 	Counterparts	  	 	3	 
	 6.
	 	Governing Law and Jurisdiction	  	 	4	 

  

  
  

Dundas & Wilson 
 Portions
of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. 

 THIS ASSIGNMENT is made on 15th March 2012 

BETWEEN: 
  

	(1)	CARDIFF PROTIDES LIMITED, a company incorporated under the Companies Acts (registered number 05455482) and having its registered office at Ty Myddfai, National Botanic Gardens of Wales, Llanarthney, Carmarthen,
Dyfed SA32 8HZ (the “Assignor”); and 

  

	(2)	NUCANA BIOMED LIMITED, a company incorporated under the Companies Acts (registered number 03308778) and having its registered office at Bassett House, 5 Southwellpark Road, Camberley, Surrey GU15 3PU (the
“Assignee”). 

 WHEREAS: 

Pursuant to the Assignment, Licence and Collaboration Agreement (as defined below), the Assignor has agreed to assign to the Assignee, and the
Assignee is willing to accept the assignment of the Assignor’s entire right, title and interest in and to the Patents (as defined below) on the terms and conditions set out in this Assignment. 

NOW IT IS AGREED as follows: 
  

	1.	DEFINITIONS AND INTERPRETATION 

  

	1.1	In this Assignment (including the Recitals), unless the context otherwise requires: 

Assignment, Licence and Collaboration Agreement means the Licence and Collaboration Agreement dated 13 October 2009 between Nucana
Biomed Limited and Cardiff Protides Limited, as amended by the Variation Agreement dated [insert date] between the same parties; 

Effective Date means the date of this Assignment; 

Patents means: 
  

	 	(i)	the patent applications listed in the Schedule; 

  

	 	(ii)	all patent applications which claim priority from the patent applications referred to in (i) above or from any patent application from which the patent applications referred to in (i) above claim priority;

  

	 	(iii)	all patents granted pursuant to the patent applications referred to in (i) and (ii) above; and 

  
  

Dundas & Wilson 
 Portions
of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. 
 1 

	 	(iv)	all reissues, extensions, substitutions, continuations, divisions, supplementary protection certificates or extensions of term relating to the patent applications and patents referred to in (i) to (iii) above; and

 Third Party means any party other than the Assignor and the Assignee. 

 

	1.2	In this Assignment unless the context demands otherwise: 

  

	 	1.2.1	words denoting the singular shall include the plural and vice versa; 

  

	 	1.2.2	words denoting a gender shall include all genders; 

  

	 	1.2.3	words denoting persons shall include corporations and all other legal entities; 

  

	 	1.2.4	a reference to a “Clause” shall be deemed to be a reference to the relevant clause of this Assignment; 

  

	 	1.2.5	the Clause headings are inserted for ease of reference and shall not affect the interpretation or construction of this Assignment or confer any right or obligations on either of the parties; and 

 

	 	1.2.6	references to any English legal term for any action, remedy, method of judicial proceeding, legal document, legal status, court, official or any legal concept or thing shall in respect of any jurisdiction other than
England be deemed to include what most nearly approximates in that jurisdiction to the English legal term. 

  

	2.	ASSIGNMENT 

  

	2.1	With effect from the Effective Date, the Assignor hereby assigns to the Assignee, and the Assignee hereby accepts the assignment of, the Assignor’s entire, right, title and interest in and to the Patents including
all statutory and common law rights. 

  

	2.2	The Assignor hereby undertakes: 

  

	 	2.2.1	at the reasonable request and cost of the Assignee to do all things and execute all such further documents, forms and authorisations as may be necessary to vest the Assignor’s entire right, title and interest in
and to the Patents in the Assignee absolutely, to register the Assignee’ title as proprietor of the Patents at relevant patent offices anywhere in the world and to provide reasonable assistance in the resolution of any question concerning the
Patents; 

  

	 	2.2.2	 at the reasonable request and cost of the Assignee to provide to the Assignee such assistance as the Assignee may
reasonably require, including but not limited to 

  
  

Dundas & Wilson 
 Portions
of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. 
 2 

	 	
executing all such further documents, forms and authorisations as may be required, to enable the Assignee to prosecute and maintain the Patents during the period from the Effective Date and
thereafter until registration of the assignment of the whole property, right, title and interest in the Patents to the Assignee; and 

  

	 	2.2.3	not, following the date of execution of this Assignment and prior to any transfer back to the Assignor of the Patents pursuant to the Assignment, Licence and Collaboration Agreement or otherwise, to assign or purport to
assign any rights in, to or over the Patents to any Third Party or grant or purport to grant to any Third Party any licence or other right or permission to use the Patents or otherwise do anything inconsistent with the assignment of the whole
property, right, title, and interest in and to the Patents to the Assignee pursuant to this Assignment. 

  

	3.	WARRANTIES AND LIABILITIES 

  

	3.1	Each party warrants to the other that it has full power and authority to enter into and to perform its obligations under this Assignment. 

 

	3.2	Other than as expressly set out in Clause 3.1 above and as contained in the Assignment, Licence and Collaboration Agreement, the Assignor gives no warranties, either express or implied, in relation to the Patents,
including without limitation any warranty that the Patents are valid, will proceed to grant and/or whether exploitation of the Patents will infringe any third party rights. 

 

	4.	ENTIRE AGREEMENT 

  

	4.1	This Assignment and the Assignment, Licence and Collaboration Agreement embody and set forth the entire agreement and understanding of the parties in respect of the assignment of the Patents and supersedes all prior
oral or written agreements, understandings or arrangements relating to the assignment of the Patents. Neither party shall be entitled to rely on any agreement, understanding or arrangement which is not expressly referred to in this Assignment in
respect of the assignment of the Patents. 

  

	4.2	Nothing contained in this Assignment or in any other document referred to or incorporated in it shall be read or construed as excluding any liability or remedy as a result of fraud. 

 

	5.	COUNTERPARTS  

  

	5.1	This Agreement may be executed in any number of counterparts, each of which, when executed and delivered, shall constitute an original, but all the counterparts shall together constitute one and the same agreement. This
Assignment shall not take effect until it has been executed by both parties. 

  
  

Dundas & Wilson 
 Portions
of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. 
 3 

	6.	GOVERNING LAW AND JURISDICTION 

 This Assignment (and any dispute or claim relating to
it, its enforceability or its termination) is to be governed by and construed and interpreted in accordance with English law. The parties irrevocably agree that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute
which may arise out of or in connection with this Assignment. 

  
  

Dundas & Wilson 
 Portions
of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. 
 4 

 This is the Schedule referred to in the foregoing Assignment of Patents made between Cardiff Protides Limited and
Nucana Biomed Limited 
 PART 1 

[***] 
  

			
	[***].	  	
		
	[***]	  	
		
	 [***]
	  	 [***]

	[***]	  	 [***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

  
  

Dundas & Wilson 
 Portions
of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. 
 5 

			
	[***]	  	 [***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

	[***]	  	
		
	[***]	  	
		
	 [***]
	  	 [***]

	[***]	  	 [***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

[***]
  

  
  

Dundas & Wilson 
 Portions
of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. 
 6 

			
	[***]	  	 [***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

	[***]	  	 [***]
  

[***]
  

  
  

Dundas & Wilson 
 Portions
of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. 
 7 

 This Deed is executed by the parties and is delivered and takes effect on the date at the beginning of this Deed.

 Executed as a Deed by Cardiff Protides Limited acting by: 

/s/ [***] 
 Signature of Director/Authorised Signatory 

[***] 
 Print name of Director/Authorised Signatory 

Executed as a Deed by Nucana Biomed Limited acting by: 

/s/ H.
Griffith                                        
                             

Signature of Director/Authorised Signatory 
 Hugh
Griffith                                        
                             

Print name of Director/Authorised Signatory 

  
  

Dundas & Wilson 
 Portions
of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of
the Securities Act of 1933, as amended. 
 8Exhibit

AMENDMENT NO. 2
TO THE
SIXTH AMENDED AND RESTATED MANAGEMENT AGREEMENT

This Amendment No. 2 (the "Amendment") to the Sixth Amended and Restated Management Agreement effective as of June 3, 2016, (as previously amended or modified, the "Management Agreement"), among Preferred Apartment Communities, Inc., a Maryland corporation (the "Company"), Preferred Apartment Communities Operating Partnership, L.P., a Delaware limited partnership ("PACOP"), and Preferred Apartment Advisors, LLC, a Delaware limited liability company (the "Manager"), is entered into as of August 31, 2017 ("Execution Date") effective as of July 1, 2017 (the "Effective Date").  Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Management Agreement.

WHEREAS, PACOP is governed by that certain Sixth Amended and Restated Agreement of Limited Partnership effective as of June 3, 2016 (as amended or modified, the "Partnership Agreement"); and

WHEREAS, upon the terms set forth in this Amendment, the Manager has agreed to amend certain terms related to certain fees payable to the Manager by the Company and PACOP.

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company, PACOP and the Manager agree to amend the Management Agreement as follows:
    
		
	1.
	Fee Modifications. Section 7 of the Management Agreement is hereby amended to:

		
	a.
	Delete in its entirety Section 7(k) and replace it with the following:

(k)   Loan Coordination Fee.  The Company will pay the Manager or its assignees a Loan Coordination Fee equal to 0.6% of: (1) the initial amount of any debt financed or refinanced, or outstanding debt assumed secured directly by any type of Real Estate Asset owned, directly or indirectly; (2) the additional amount of any supplemental financing secured directly by any type of Real Estate Asset owned, directly or indirectly; or (3) the Company’s allocable portion of the fees in items 7(k)(1) – (2) related to any type of Real Estate Asset owned through a Joint Venture, based on the purchase price or other valuation of the Joint Venture and the Company's ownership percentage (defined as the percentage of the equity investment by all Company Entities in the Joint Venture compared to the total of all equity investments in the Joint Venture).  The Company shall pay to the Manager or its permitted assignees the Loan Coordination Fee promptly upon the closing of the financing or refinancing.
		
	b.
	Add the following Section 7(m):

(m)    Acquisition Fee.  The Company shall pay an Acquisition Fee to the Manager or its assignees as compensation for services rendered in connection with the investigation, selection and acquisition (by purchase, investment or exchange) of Investments.  The total Acquisition Fee payable to the Manager or its assignees shall equal 1.0% of the purchase price of Real Estate Assets, along with reimbursement of Acquisition Expenses actually incurred by the Manager or any of its Affiliates; provided, however, that no Acquisition Fee will be payable until the Closing Date, although such fees may accrue before the Closing Date.  The purchase price of Real Estate Assets shall equal the amount paid or allocated to the acquisition (by purchase, investment or exchange) of the Real Estate Assets exclusive of expenses related thereto, and exclusive of Acquisition Fees.  The purchase price allocable for an Investment held through a Joint Venture shall equal the product of (i) the purchase price of, or the amount advanced for, the Investment, as applicable, 

determined as stated above, and (ii) the direct or indirect ownership percentage in the Joint Venture held directly or indirectly by any Company Entity.  For purposes of this paragraph, “ownership percentage” shall be the percentage of capital stock, membership interests, partnership interests or other equity interests held by any Company Entity, without regard to classification of such equity interests.  The Company shall pay to the Manager or its assignees the Acquisition Fee promptly upon the closing of the Investment, subject to the proviso set forth above.

		
	2.
	Definitions.  Section 1(a) of the Management Agreement is amended as follows:

		
	a.
	the definition of "Acquisition Expenses" is deleted and replaced with the following:

“Acquisition Expenses” means any and all expenses, exclusive of Acquisition Fees, Loan Origination Fees and Loan Coordination Fees, incurred by the Company, the Manager or any of their respective Affiliates in connection with the selection, evaluation, acquisition, origination, making or development of any Investment, whether or not acquired, including legal fees and expenses, travel and communications expenses, property inspection expenses, third party brokerage or finder’s fees, costs of appraisals, nonrefundable option payments on property not acquired, accounting fees and expenses, title insurance premiums and expenses, survey expenses, closing costs and the costs of performing due diligence.

		
	b.
	the following definition(s) are added in alphabetical order:

"Acquisition Fee" has the meaning set forth in Section 7(m).

		
	3.
	Ratification; Effect on Management Agreement.

		
	a.
	Ratification.  The Management Agreement, as amended hereby, shall remain in full force and effect and is hereby ratified and confirmed in all respects.

		
	b.
	Effect on the Management Agreement.  On and after the date hereof, each reference in the Management Agreement to "this Agreement," "herein," "hereof," "hereunder," or words of similar import shall mean and be a reference to the Management Agreement as amended hereby.

[Signature page follows.]

IN WITNESS WHEREOF, each of the parties hereto has executed this Amendment as of the Execution Date, effective as of the Effective Date.
PREFERRED APARTMENT COMMUNITIES, INC.
		
	By:
	/s/ John A. Williams         
Name:  John A. Williams 
Title: Chief Executive Officer

PREFERRED APARTMENT COMMUNITIES OPERATING PARTNERSHIP, L.P.
		
	By:
	Preferred Apartment Communities, Inc. 
its General Partner

		
	By:
	/s/ John A. Williams         
Name: John A. Williams 
Title: Chief Executive Officer

PREFERRED APARTMENT ADVISORS, LLC
		
	By:
	NELL Partners, Inc., 
its Managing Member

		
	By:
	/s/ John A. Williams     
Name: John A. Williams 
Title: Chief Executive Officer

[Signature Page to Amendment No. 2 to Sixth Amended and Restated Management Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]